Snowdrift Parent Corp
No SEC Form 4 filings for $SCIP in the last 30 days.
See all $SCIP insider activity →Scipher Medicine Corporation disclosed a 10.4% stake in Chemomab Therapeutics, buying 932,203 ADSs for $1.1 million. The purchase supports their planned merger, expected to close in Q1 2027, with the combined company trading on Nasdaq as SCIP. Scipher used convertible note proceeds and working capital for the purchase.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning SCIP (Snowdrift Parent Corp). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
The stake signals progress on the merger and may lift Scipher's share price while putting short‑term pressure on Chemomab as it raises financing.
AlphAI scores every news story that mentions SCIP with an AI model for sentiment and relevance, and aggregates insider trades from Snowdrift Parent Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Scipher Medicine Corporation disclosed a 10.4% stake in Chemomab Therapeutics, buying 932,203 ADSs for $1.1 million. The purchase supports their planned merger, expected to close in Q1 2027, with the combined company trading on Nasdaq as SCIP. Scipher used convertible note proceeds and working capital for the purchase.
